Estrogen Deprivation Therapy in Ovarian Cancer: An Opportunity Ovarian Cancer and Us OVARIAN CANCER and US Ovarian Cancer and Us

Blog Archives: Nov 2004 - present


Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Monday, May 23, 2016

Estrogen Deprivation Therapy in Ovarian Cancer: An Opportunity

Correspondence - open access
 May 23, 2016 

To the Editor:

The recent case report by Lamm et al1 about a patient with a granulosa cell tumor of the ovary describes a dramatic therapeutic response with the aromatase inhibitor letrozole (2.5 mg/day) after the failure of long-term pseudo-adjuvant therapy with tamoxifen (40 mg/day). This clinical observation can now be linked back to the recent report by Eeles et al2 on the safety of adjuvant hormone therapy (AHT), that is, estrogen treatments to ameliorate severe menopausal symptoms. The report2 documented the survival and disease outcomes in women with epithelial ovarian cancer. Our letter provides an opportunity to decipher a unifying mechanism for estrogen action that could be deployed for the benefit of patients with ovarian cancer...... 


  1. 1.
  2. 2.
  3. 3.
  4. 4.
  5. 5.
  6. 6.
  7. 7.
  8. 8.
  9. 9.
  10. 10.

Related Article



Post a Comment

Your comments?